Maravai Lifesciences Holdings (MRVI) Gains from Investment Securities (2022 - 2025)

Maravai Lifesciences Holdings' Gains from Investment Securities history runs 4 years deep, the most recent figure standing at $140000.0 for Q2 2025.

• In Q2 2025, Gains from Investment Securities rose 111.72% year-over-year to $140000.0; the TTM figure through Jun 2025 stood at -$1.9 million (up 58.42% YoY), while the FY2024 annual figure was -$2.0 million, up 39.04% from the prior year.
• Gains from Investment Securities for Q2 2025 stood at $140000.0, up from -$630000.0 in the prior quarter.
• The five-year high for Gains from Investment Securities was $2.4 million in Q3 2023, with the low at -$7.8 million in Q1 2022.
• The 4-year median for Gains from Investment Securities is -$1.8 million (2023), against an average of -$2.6 million.
• The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities plunged 107.46% in 2024, then surged 111.72% in 2025.
• Maravai Lifesciences Holdings' Gains from Investment Securities stood at -$7.8 million in 2022, then soared by 56.99% to -$3.4 million in 2023, then jumped by 81.22% to -$630000.0 in 2024, then soared by 122.22% to $140000.0 in 2025.
• Business Quant data shows MRVI's Gains from Investment Securities at $140000.0 in Q2 2025, -$630000.0 in Q4 2024, and -$178000.0 in Q3 2024.